Long-term outcome of (neo)adjuvant zoledronic acid therapy in locally advanced breast cancer.
Andrew P JalloukSriram ParavastuKatherine WeilbaecherRebecca L AftPublished in: Breast cancer research and treatment (2021)
Addition of ZOL to neoadjuvant therapy did not significantly affect clinical outcomes in the overall study population but was associated with increased extra-skeletal recurrence and a trend towards worse survival in ER+/HER2- patients younger than age 45. These findings suggest caution when using zoledronic acid in young, premenopausal women with locally advanced breast cancer and warrant further investigation. Clinical Trial Registration Number NCT00242203, Date of Registration: 10/17/2005.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- clinical trial
- radiation therapy
- end stage renal disease
- phase ii study
- ejection fraction
- newly diagnosed
- prognostic factors
- early stage
- peritoneal dialysis
- chronic kidney disease
- randomized controlled trial
- free survival
- postmenopausal women
- lymph node
- open label
- study protocol
- middle aged
- phase ii
- cell therapy
- phase iii
- double blind